SWOG clinical trial number
CTSU/E2108

A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer.

Closed
Phase
Abbreviated Title
Randomized Ph III of Early Local Therapy for Intact Primary Tumor with MBC
Activated
03/15/2011
Closed
07/23/2015
Participants
CTSU

Research committees

Breast Cancer

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2020

A randomized Phase Ill trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo Stage IV breast cancer: a trial of the ECOG-ACRIN Research Group (E2108)

S Khan;F Zhao;L Solin;L Goldstein;D Cella;M Basik;M Golshan;T Julian;B Pockaj;C Lee;W Razaq;J Sparano;G Babiera;I Dy;S Jain;P Silverman;C Fisher;A Tevaarwerk;L Wagner;G Sledge J Clin Oncol 38: 2020 (suppl; abstr LBA2); American Society of Clinical Oncology Annual Meeting (5/29-6/2/20, Chicago, IL), oral, plenary

Other Clinical Trials

SWOG Clinical Trial Number
CTSU-A012301

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Research Committee(s)
Breast Cancer
Activated
02/05/2025
Open
Phase
SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
21%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
31%
Open
Phase